Kodiak Sciences Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Segment Information
- Segment Information
The Company operates and manages its business asone operating and reportable segment, which is the business of researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. The chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM uses net loss to allocate resources and assess performance when making decisions on the timing and extent of the Company's development programs for its product candidates. The assets are managed on a consolidated basis as reported on the condensed consolidated balance sheets.
The significant expense categories within net loss are presented on the condensed consolidated statements of operations. Research and development expenses have been disaggregated as follows (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Tarcocimab program expenses | $9,406 | $11,886 | $19,351 | $26,162 |
| KSI-501 program expenses | 12,746 | 3,862 | 22,603 | 7,162 |
| KSI-101 program expenses | 12,279 | 1,447 | 19,279 | 2,364 |
| ABC Platform and other program expenses | 3,607 | 6,421 | 7,373 | 12,066 |
| Payroll and personnel expenses | 13,672 | 14,109 | 27,851 | 28,379 |
| Facilities and other research and development expenses | 4,373 | 5,035 | 8,173 | 10,271 |
| Total research and development expenses | $56,083 | $42,760 | $104,630 | $86,404 |
Beginning in 2026, KSI-501 and KSI-101 program expenses are presented as separate line items given increased clinical activities within both programs. Previously, the two programs were presented as a single line item.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.